- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Debra Patt: Do Not Delay Diagnostic Visits for Breast Cancer
Debra Patt, MD, PhD, MBA, executive vice president of Texas Oncology, explains recommendations for annual mammography screenings after COVID-19 vaccination and why guidelines differ for diagnostic visits.
Because lymph nodes tend to swell, women should wait at least 6 weeks when scheduling a screening mammogram after COVID-19 vaccination; however, diagnostic visits for lumps should not wait, emphasized Debra Patt, MD, PhD, MBA, executive vice president of Texas Oncology.
Transcript
Is there an optimal waiting period between COVID-19 vaccination or booster dosing and scheduling either a mammogram or an annual gynecological visit?
If someone has a screening mammogram—meaning that they don’t have any symptoms, but they’re just getting their routine annual screen—then, on average, they should probably wait about 6 weeks after they get a vaccination for coronavirus.
The reason for this is because sometimes when you get a vaccination, it can cause lymph nodes in the armpit or the axilla to become enlarged. There’s nothing wrong with them, it’s just a natural result of having a vaccination in your arm that is stimulating your immune system. Your lymph nodes are kind of doing what they’re supposed to be doing. They respond to it, and whenever we see that happen, which is common, it usually resolves after about 6 weeks. So we think if people are getting a screening mammogram, then they should probably wait about 6 weeks after COVID-19 vaccination.
That’s different, though, than women who are getting a diagnostic mammogram. If you have a mass in your breast, you should not delay in getting it worked up. And there’s really not an issue with cervical cancer screening and the timing of vaccination.
What's at Stake as Oral Arguments Are Presented in the Braidwood Case? Q&A With Richard Hughes IV
April 21st 2025Richard Hughes IV, JD, MPH, spoke about the upcoming oral arguments to be presented to the Supreme Court regarding the Braidwood case, which would determine how preventive services are guaranteed insurance coverage.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Orca-T showed lower rates of graft-vs-host disease or infection compared with allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome (MDS) or acute leukemias in the Precision-T trial, Caspian Oliai, MD, MS, UCLA Bone Marrow Transplantation Stem Cell Processing Center, said.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
What the Updated Telephone Consumer Protection Act Rules Mean for Health Care Messaging
April 4th 2025As new Federal Communications Commission rules take effect April 11, 2025, mPulse CEO Bob Farrell explains how health organizations can stay compliant while building patient trust through transparency and personalized engagement.
Read More
High-Impact Trials at ACC.25 Signal Shift in Chronic Disease Treatment
April 4th 2025Experts highlight groundbreaking research presented at the American College of Cardiology Annual Scientific Session (ACC.25), which emphasized a shift toward more personalized, evidence-based treatment strategies.
Read More
